View Item 

Show simple item record

Ross MAP Team: UM Center for Discovery of New Medicines (CDNM) Final Report

dc.contributor.authorCamalo, Patrick
dc.contributor.authorHashimoto, Ichiro
dc.contributor.authorKerppola, Marianna
dc.contributor.authorKoul, Neha
dc.date.accessioned2020-12-21T16:26:34Z
dc.date.available2020-12-21T16:26:34Z
dc.date.issued2015-04-29
dc.identifier.urihttps://hdl.handle.net/2027.42/163766
dc.descriptionAs part of the MBA core curriculum at UM Ross School of Business, MBA students engage in a Multi-Disciplinary Action Project (MAP). Students work in teams to tackle a real-world problem currently faced by an organization, while applying the principles and skills learned during their first year core courses. The 2015 MAP team for CDNM is comprised of four members (see Appendix A for biographies). The 2015 MAP team was enlisted to develop a strategic plan that will position CDNM as a leader in academic drug discovery. The team conducted a landscape assessment of academic drug discovery, identified challenges and opportunities for financial sustainability, and developed a data-driven, strategic plan that enables CDNM to improve drug discovery at UM. The project scope focused on the following: ● Explore the current drug discovery landscape by benchmarking CDNM against other academic drug discovery centers (ADDCs) and identifying opportunities for industry partnership ● Evaluate the current financial and operational structure for CDNM; provide recommendations for reaching financial and operational sustainability ● Evaluate the perception of drug discovery at University of Michigan among Principal Investigators (PIs) and assess the brand equity of CDNM ● Provide an educational strategy to incite behavior change and interest towards drug discovery among PIs at University of Michiganen_US
dc.description.abstractThe drug discovery landscape is complex, evolving, and increasingly requires the innovation of academia. Opportunities for translational research have expanded as academic drug discovery centers (ADDCs) proliferate, biopharma externalizes innovation in its pipeline, and venture capitalists shift funding to preclinical projects. For the Center for the Discovery of New Medicines (CDNM) to guide the drug discovery community at the University of Michigan, bridge gaps between principal investigators and industry, and become a leader among ADDCs, we a set of recommendations.en_US
dc.language.isoen_USen_US
dc.subjectdrug discoveryen_US
dc.subjectCenter for the Discovery of New Medicinesen_US
dc.subjectMichigan Drug Discoveryen_US
dc.subjectRoss MAPen_US
dc.titleRoss MAP Team: UM Center for Discovery of New Medicines (CDNM) Final Reporten_US
dc.typeProjecten_US
dc.subject.hlbsecondlevelBiomedical Engineering
dc.subject.hlbtoplevelHealth Sciences
dc.contributor.affiliationumLife Sciences Instituteen_US
dc.contributor.affiliationumRoss School of Businessen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163766/1/MAP+Team+171+Final+Report.pdf
dc.description.filedescriptionDescription of MAP+Team+171+Final+Report.pdf : Report
dc.description.depositorSELFen_US
dc.owningcollnameLife Sciences Institute (LSI)


Files in this item

Name:
MAP+Team+171+Final+Report.pdf
Size:
1.993MB
Format:
PDF
Description:
Report
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.